Friedman Kaplan Advises PAVmed and Lucid Diagnostics in Connection with Lucid Diagnostics’ Initial Public Offering

October 18, 2021

Friedman Kaplan recently advised its clients PAVmed Inc. and its majority-owned subsidiary Lucid Diagnostics Inc. (“Lucid”) on various aspects of Lucid’s recently consummated initial public offering.  Corporate partner Michael Gordon led Friedman Kaplan’s representation on the transaction.

PAVmed (NASDAQ: PAVM) is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing a broad spectrum of unmet clinical needs.  Lucid (NASDAQ: LUCD) is a commercial-stage cancer prevention medical diagnostics company focused on patients with gastroesophageal disease who are at risk of developing esophageal precancer and cancer.  

To celebrate this milestone, Michael Gordon accompanied the rest of the Lucid team at the Nasdaq closing bell ringing ceremony on October 15.  To view footage from the ceremony, please visit

Practice Areas